# Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)

> **NCT07327840** · PHASE2 · RECRUITING · sponsor: **Kylonova (Xiamen) Biopharma co., LTD.** · enrollment: 204 (estimated)

## Conditions studied

- Lipoprotein Disorder

## Interventions

- **DRUG:** Kylo-11 or matched placebo

## Key facts

- **NCT ID:** NCT07327840
- **Lead sponsor:** Kylonova (Xiamen) Biopharma co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2027-02-28
- **Final completion:** 2028-08-31
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07327840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07327840, "Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07327840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*